PET/CT scan for tumors with positive SSTR signals
Part of Cancer clinical trials.
This trial looks at how a special PET/CT scan using a substance called Al18F-octreotide can find and evaluate tumors that show a certain target signal (SSTR). It may help doctors better see where the tumor is and guide next steps in care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a suspected or confirmed tumor that tests positive for SSTR (a specific target on the tumor).
- You can sign a written consent form to join the study.
- You are willing and able to follow all study instructions and appointments.
- You are not pregnant.
- You are not breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special type of PET scan (called SSTR PET/CT) to look at tumors that may have a specific receptor. The scan helps doctors see where these tumors are and how active they are.
This trial tests a new radioactive drug (177Lu-TATE-RGD) that targets two specific markers on tumor cells. It is for people whose cancer has not responded to standard treatments and whose tumors show high levels of these markers on a PET scan.
This trial uses a new kind of PET/CT scan to take detailed pictures of solid tumors such as melanoma, liver, lung, breast, pancreatic, or ovarian cancer. The scan might help doctors find cancer more clearly.
This trial tests a new way to take PET scan pictures using a very low amount of a radioactive tracer that targets a protein called SSTR2. It is designed to see if these scans can work well while reducing radiation exposure for patients with certain types of tumors.
This study uses a special PET scan called 18F-AlF-NOTA-Octreotide to get clear images of neuroendocrine tumors. It can help doctors see where the tumors are and how active they are, which may guide treatment decisions.
This study compares two special PET/CT scan tracers—68Ga-FAPI-LM3 and 18F-FDG—to see how well they detect cancer that shows FAP or SSTR2 signals. It may help doctors choose better imaging to find or assess certain tumors.
Hear when a new SSTR Positive Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.